Efficacy and safety of topical 3% minoxidil for facial hair enhancement in transmen: a randomized, double-blind, placebo-controlled trial

Key Points

• To evaluate the efficacy and safety of topical 3% minoxidil for enhancing facial hair in transgender men undergoing gender-affirming hormone therapy.
• Randomized, double-blind, placebo-controlled trial design.
• Participants selected from transgender men receiving gender-affirming hormone therapy.
• Topical application of 3% minoxidil compared to placebo over a set duration.
• Topical 3% minoxidil demonstrated significant improvements in facial hair growth compared to placebo.
• Participants reported high tolerability and minimal adverse effects associated with minoxidil use.